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ABSTRACT 
Aims 
Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a high grade, 
aggressive tubulopapillary carcinoma, arising predominantly in the setting of the hereditary 
leiomyomatosis-renal cell carcinoma syndrome of familial uterocutaneous leiomyomatosis and 
deficiency of fumarate hydratase. In contrast, succinate dehydrogenase (SDH)-deficient RCC is 
a lower grade oncocytic carcinoma with cytoplasmic flocculence/vacuolation and inclusions, 
arising mostly in individuals harboring germline mutations of subunit B of the SDH complex 
(SDHB). Recently, we have identified four cases of a novel type of FH-deficient RCC, where the 
morphology observed was that of an oncocytic carcinoma, reminiscent of SDH-deficient RCC. 
 
Methods and Results 
These distinctive, low grade oncocytic neoplasms, with solid, nested, and focally tubular 
architecture (0.2-9cm) arose in four males (11-41y). Uniform cytology of polygonal cells with 
flocculent, vacuolated eosinophilic cytoplasm with scattered inclusions, fine chromatin, and 
inconspicuous nucleoli was apparent. Despite these features suggestive of SDH-deficient RCC, 
each tumor was confirmed as an FH-deficient carcinoma with retained SDHB expression. One 
case showed a synchronous, anatomically separate, typical high grade FH-deficient RCC; one 
other showed such a tumor at nephrectomy 4 years later. No progression has been noted at 3 
and 7 years in the cases with only the SDH-like lesions; the two cases with separate, typical FH-
deficient RCCs progressed. 
 
Conclusions 
In summary, we characterize a novel oncocytic type of FH-deficient RCC with striking 
resemblance to SDH-deficient RCC, posing a diagnostic challenge and raising concerns for 
sampling and multifocality for syndrome-associated cases under surveillance protocols.  
 
Key Words: renal cell carcinoma; hereditary leiomyomatosis-renal cell carcinoma syndrome; 
succinate dehydrogenase-deficient renal cell carcinoma; fumarate hydratase-deficient renal cell 
carcinoma, oncocytic carcinoma.   
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INTRODUCTION 
 Recent series1, 2 have shed much light on the clinicopathologic features of succinate 
dehydrogenase (SDH)-deficient renal cell carcinoma (RCC)3, 4. Proceeding from the initial 
observation of kidney tumors in kindreds with germline SDHB mutation and predisposition to 
epithelioid gastrointestinal stromal tumors (GISTs) and multiple pheochromocytomas and 
paragangliomas5, greater experience suggests these RCCs are morphologically distinctive4, are 
under-recognized but rare, arise with slight male predominance in middle aged adults, and are 
frequently bilateral1, 2. The morphology is quite characteristic, of tumors composed of small 
nests and sheets of oncocytic polygonal cells, unencapsulated, and sometimes entrapping 
peripheral benign tubules. Cytologically they show vacuolated pink cytoplasm and variably 
prominent, pale eosinophilic inclusions, thought to represent dysfunctional mitochondria6. The 
nuclear features are usually low grade and monotonous, with what we have called a 
neuroendocrine-like chromatin pattern2. A subset of cases, however, have shown sarcomatoid 
transformation with overt nuclear atypia and aggressive course. While most SDH-deficient 
RCCs that have been tested have b en shown to harbor SDHB mutations, scattered reports 
have identified SDHA and SDHC mutations as well7-9. In any case, to assist in their recognition, 
SDHB immunohistochemistry (IHC) has been used for detection of tumors with SDH subunit 
mutations based on consistent loss of SDHB expression by IHC, whether there is SDHA, SDHB, 
SDHC or SDHD mutation, due to mitochondrial complex II instability3.  
 In contrast, hereditary leiomyomatosis-RCC syndrome (HLRCC) represents another 
RCC syndrome, related to germline mutation of the gene fumarate hydratase (FH), consisting of 
highly penetrant cutaneous (>90% of males and females) and uterine (~70% of females) 
leiomyomatosis with less prevalent (10-30%)10-12 “type 2 papillary” RCC13 arising in both males 
and females over a diverse age range. Adrenocortical adenomas have been reported in ~10% 
of affected subjects14. The RCCs arising in HLRCC show a much more variable, high grade 
morphology, including papillary, tubulopapillary, cribriform, cystic, and infiltrative collecting-duct 
like patterns15, 16. Prospective recognition of these tumors is emphasized due to their remarkable 
aggression, for which immunohistochemistry for FH (lost in most cases with mutations17) and for 
aberrant succination of nuclear and cytoplasmic proteins (2-succinylcysteine, 2SC16) has been 
used. While most cases are thought to occur with germline rather than somatic FH mutations18, 
recent data identify apparently somatic mutations in sporadic uterine leiomyomas19 and even 
high grade papillary renal cell carcinomas20. In any case, a great many cases showing FH-
deficiency by immunohistochemistry do not show stigmata of this syndrome. For this reason, we 
have recently proposed21 a term, FH-deficient RCC, for provisional use, with recommendation of 
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genetic consultation, in morphologically and immunohistochemically suggestive cases, without 
apparent syndromic features and unavailable genotyping17, 22.  
 In a recent interinstitutional review of FH-deficient RCCs22, we noted several 
morphologic outliers. Based on prior experience with SDH-deficient RCC2, we noted tumors with 
a low grade oncocytic morphology, suggestive of SDH-deficiency, among cases with clinical, 
morphologic, immunohistochemical, or molecular evidence suggestive of FH-deficiency. Careful 
review of published cases of HLRCC identified another case with such morphology23, which we 
also reviewed. Intrigued by the morphologic overlap of these carcinomas across syndromes 
defined by disparate classic phenotypes but shared metabolic alterations, we present the 
findings herein.  
 
METHODS 
 
Cases, Immunohistochemistry and Molecular Studies 
In accordance with the ethical principles of the Declaration of Helsinki, under IRB-
approved protocols (VCU IRB #HM20002545, valid through 4/26/2017; CSMC IRB # 
Pro00027348; valid through 1/31/2018), granting waivers of consent, cases of renal cell 
carcinoma arising in the setting of known or suspected HLRCC were identified retrospectively 
from the files of the authors. All sections of every case were obtained and reviewed, and 
deidentified clinicopathologic data collected. One cas  has been reported previously by Alrashdi 
et al.23, which was also re-reviewed with extended follow-up. Routine immunohistochemistry 
(IHC), using protocols and evaluation as reported previously for FH22 and 2SC16, and SDHB and 
SDHA2 was employed. For one case, multiplexed PCR-based next-generation sequencing 
(NGS) of tumor genomic DNA was performed using the Ion Ampliseq Comprehensive Cancer 
Panel (CCP) targeting 409 cancer-related genes, including FH (and SDHB), with validation and 
analysis pipeline, and copy number alteration detection as reported24-26 using cutoffs for variant 
detection exactly as reported22.  
 
RESULTS 
Clinicopathologic Features 
Table 1 details the clinicopathologic findings per case. The tumors arose in four males 
aged 11-41. Presenting stimuli included from left back and abdominal pain (Case 1), imaging 
findings performed under syndromal surveillance (Case 2), abdominal pain and anemia with 
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history of polycystic kidneys by imaging (Case 3), and incidental enlarged kidney on MRI (Case 
4).  The oncocytic tumors were multifocal (Figure 1A) in two cases (1&3) and unifocal in two 
(Cases 2&4). Two cases (3&4) showed separate (one anatomically distant from the oncocytic 
tumor; one presenting 4 years later at completion nephrectomy) high grade FH-deficient RCCs. 
Two cases provided strong evidence of HLRCC, including concurrent multiple cutaneous 
leiomyomata (Case 1), and germline mutation-confirmed HLRCC (Case 2). Case 3 also had 
suggestive history, including personal history of a first-degree relative having succumbed to 
metastatic RCC and personal history of “multicystic kidneys” by imaging. No data are available 
regarding HLRCC-associated stigmata for Case 4. In terms of clinical outcome, the two cases 
with only low grade oncocytic carcinomas are free of disease at nearly 3 years and more than 7 
years post-nephrectomy.  The two cases with separate high grade tumors showed progression, 
at presentation in Case 3 (liver metastasis showing morphology of the high grade tumor at 
frozen) and at 3 months post completion nephrectomy (though after 4 years had elapsed 
without progression since the partial nephrectomy with the oncocytic RCC) in Case 4.    
  The specimens evaluated wer  3 radical and 1 partial nephrectomy. The nephrectomy of 
Case 1 harbored an ipsilateral adrenocortical adenoma (2.7cm) (Figure 1B), while cutaneous 
biopsies performed concurrently with nephrectomy for suspected metastasis (Figure 1C) 
proved to be cutaneous, pilar-type leiomyomatosis (Figure 1D). The tumors were described as 
yellow or tan (Figure 2A) and measured at gross exam from 0.2cm up to 9cm. In three cases, 
these were seen adjacent to variable background cystic change (Figure 3A, Figures 4A&C, 
Figure 5A). In each case, the tumors were grossly unencapsulated but appeared non-infiltrative 
of the adjacent structures, bulging but confined to the kidney.    
 
Histologic Features 
  Morphologically, these tumors showed a low grade oncocytic morphology, with 
confluent solid or nested confluent growth and prominent nodularity, closely juxtaposed to the 
adjacent renal parenchyma (Figure 2B, 3A). At higher power, the architecture showed a mixed 
pattern, in some areas with tubular morphology (Figures 2C-D, 3B-C), sometimes dilated to 
impart a microcystic appearance with pink luminal contents (Figure 2C). One nodule 
demonstrated prominent stromal edema with dispersed tubular aggregates of cells (Figure 2D); 
in other foci tubular growth was more packed (inset). Cytologically, consistent oncocytic features 
were seen, with tumors composed of polygonal cells with eosinophilic cytoplasm with scattered 
vacuoles and predominantly round, regular nuclei (Figure 2E, 3C, 4B&D, 5B). The chromatin 
was finely granular; many examples showed micronucleoli that were not prominent at 10X 
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(ISUP grade 2). Numerous stromal mast cells were apparent in many areas (Figure 2E). All 
cases demonstrated variable cytoplasmic flocculence or vacuolation; in three cases (2-4), 
cytoplasmic inclusions of pink hyaline material reminiscent of those that have been described in 
SDH-deficient RCC were readily identifiable (Figure 3C, 5B). No coagulative tumor cell  
necrosis was identified in any of these tumors, nor were features of vascular invasion present, 
including in the multifocal cases, which were interpreted histologically as independent neoplastic 
foci.  
 Two cases (3&4) demonstrated separate RCCs with features that have been associated 
with typical high grade FH-deficient RCC. Case 3 demonstrated a 3.5cm tumor, in the upper 
pole of the kidney, distant from the oncocytic tumors, with prominent tubulocystic morphology 
and poorly differentiated, solid areas with cribriform and syncytial appearance (Figure 4E-F); a 
metastatic liver lesion with this morphology was present at nephrectomy. In Case 4, a 
completion nephrectomy was performed 4 years after the partial nephrectomy (that had shown 
the low grade oncocytic RCC), and a 5cm high grade RCC with tubulocystic and infiltrative 
collecting duct carcinoma-like areas was identified, invasive of renal sinus adipose (Figure 5C). 
In both of these cases the cytology of the high grade tumors was high grade (ISUP 3 to 4) with 
syncytial appearance and prominent, viral inclusion-like nucleoli with perinuclear halos (Figure 
5D).  
 
Immunohistochemical and Molecular Features 
In all four cases, the oncocytic tumors showed strong/diffuse retained expression of both 
SDHB and SDHA, with loss of expression of FH and induction of strong nucleocytoplasmic 2SC 
positivity (Figures 2F, 3D, 5B). PAX8 expression was diffuse in all the oncocytic tumors (not 
pictured), with variable, patchy expression of pancytokeratin AE1/AE3 and the oncocytic renal 
neoplasia-associated marker, kidney-specific cadherin (Ksp-cadherin) as detailed in Table 2. Of 
note, the cutaneous leiomyoma seen in Case 1 also demonstrated SDHB/SDHA positivity with 
loss of FH (Figure 1D), while the separate high grade carcinomas seen in Cases 3&4 were both 
FH-deficient. In Case 3, NGS was performed on the low grade oncocytic RCC, identifying 
homozygous FH frameshifting mutations (p.K80fs). This mutation was identical to the 
homozygous FH mutations observed in the anatomically separate high grade FH-deficient 
RCC22. Nevertheless, comparing genome wide copy number alterations between these two 
separate carcinomas, the oncocytic tumor lacked the copy number gains (chromosome 8q) and 
losses (chromosome 18) seen in the high grade FH-deficient carcinoma (Figure 4H). Consistent 
with the IHC findings, no SDHB mutations were identified.  
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DISCUSSION 
 Recent years have seen recognition of distinctive morphologic features of subtypes of 
RCC associated with genetic syndromes, including the succinate dehydrogenase (SDH)-
deficient RCCs associated with familial paraganglioma/pheochromocytoma syndromes3, 4 and 
the fumarate hydratase (FH)-deficient RCCs associated with hereditary leiomyomatosis-RCC 
syndrome15. From the standpoint of the diagnostic pathologist, recognition of these RCC 
subtypes is of utmost importance due to the need to risk stratify individual tumors based on 
increasing published experience1, 2, 17, 22 and to recommend genetic counseling and testing for 
patients and their families.  
 With regards to the present cases, first, we note that the evidence available suggests 
that three of these cases represent HLRCC, though proof of germline mutation of FH 
(observation of the same constitutional FH mutation in two separate generations) is unavailable 
except for the second case, which arose in a patient from a well-characterized HLRCC family23. 
The first case, arising in an individual showing multiple, histologically confirmed cutaneous 
leiomyomas, and the third case, with the separate “type 2 papillary” RCC or “collecting duct 
carcinoma”27 before the age of 40 and with an affected first degree relative, would meet the 
criteria reported by Menko et al.28 for likely HLRCC.  Quite suggestive of a constitutional 
mutation, this third case also had the same homozygous FH mutation detected from the 
anatomically separate SDH deficient-like and typical high grade FH-deficient RCCs. Notably, no 
data regarding family history of HLRCC or personal or family history of uterocutaneous 
leiomyomatosis is available for the fourth case. In light of recently reported data that uterine 
leiomyomata and even FH-mutant RCCs may occur through somatic mutations19, 20, we can only 
regard this case as an FH-deficient RCC21, 22.  
 We acknowledge the wisdom of the opinion held by some that explicit observation of a 
germline FH mutation remains the true gold standard for HLRCC diagnosis15, 16; in three of our 
cases, this will remain impossible (not allowed under the retrospective protocols governing the 
study). Our inability to retrospectively perform genetic testing for constitutional changes in FH 
and SDHB remains the most important limitation of this study. Moreover, it underscores the 
essential role of surgical pathologist in early recommendation of genetic consultation for patients 
with tumors in in this morphologic and clinical spectrum. Only accumulated, carefully genetically 
documented clinical experience will answer the question of whether FH-deficient or SDH-
deficient RCCs occur sporadically by somatic mutation at any frequency. Indeed, SDH-deficient 
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paragangliomas29, 30 and other lesions with only somatic SDH subunit mutations 31 have been 
described, making this issue all the more salient.  
 With regard to the oncocytic tumors, we do not argue that these tumors represent 
perfect morphologic phenocopies of the most characteristic SDH-deficient RCCs. However, in 
each case, when encountered after our prior studies of SDH-deficient RCCs2, we were 
sufficiently suspicious that we ordered SDH-deficient workup (by IHC). Each case demonstrated 
oncocytic morphology with stromal mast cells and areas of distinctive cytoplasmic flocculence 
and vacuolation, with at least focal inclusion-like formations. The predominant architectural 
pattern was solid or nested, though tubular or pseudoglandular pattern, reported previously in 
SDH-deficient RCCs1, was prominent in areas of two of the cases. Pancytokeratin AE1/AE3 was 
positive in a variable, patchy manner; Ksp-cadherin was positive in three cases, similar to SDH-
deficient RCC2 and as is characteristic of oncocytic renal neoplasia generally32, as was PAX8. 
Most important, however, was the observation in all three tumors of consistently retained SDHB 
in a strong diffuse manner, reflective of an intact SDH complex33. In contrast, FH expression 
was lost and 2SC expression strongly, diffusely induced in a nucleocytoplasmic manner, a 
pattern that has proven in our experience16, 22, 34 and that of others17, 35, 36 to be demonstrative of 
FH mutation and loss of function. Thus, we interpret the FH-2SC+ immunophenotype in each of 
these tumors as confirmatory of their specificity to FH-deficiency and exclusive of their 
representing an etiologically unrelated epiphenomenon (sporadic-type carcinomas arising in the 
polycystic background, for instance).  
In summary, we describe four intriguing cases, tumors with a low grade oncocytic 
morphology and variable cytoplasmic vacuolation and flocculence.  On morphologic grounds, 
these tumors were first deemed quite reminiscent of SDH-deficient renal cell carcinoma. 
However, immunophenotypic workup points to their representing a novel morphologic type of 
FH-deficient carcinoma, including loss of FH expression, induction of strong diffuse 
nucleocytoplasmic 2SC immunostaining, and retained expression of SDHB, to say nothing of 
the clinical features quite suggestive of (or confirmed) HLRCC in three of them. We speculate 
that these tumors represent as yet another example of an emerging phenomenon of phenotypic 
“crossover lesions” between FH-deficient and SDH-deficient syndromes, analogous to recently 
described paragangliomas occurring the setting of germline FH mutation35, 37, 38. 
Two of these novel cases also raise the precedent that when not associated with a high 
grade FH-deficient RCC, this oncocytic tumor type could be associated with a more favorable 
outcome. High grade FH-deficient RCCs have been associated with progression and/or death of 
disease in 30-80%15, 17, 22. Our experience with these low grade oncocytic tumors emphasizes 
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the importance of morphologic context for interpreting IHC and molecular findings. Despite the 
shared “FH-deficient RCC” status of both the low grade oncocytic tumors and typical high grade 
FH-deficient RCCs, such a high risk label would have been inappropriate for the low grade 
tumors given that progression was only seen in cases with a separate high grade tumor. 
Certainly, much greater study is needed, and prospectively we recommend careful inquiry 
regarding the nature of any syndromal stigmata and use of SDHB, SDHA, and FH IHC, as well 
as genetics referral, for concerning cases. Moreover, given the presence of anatomically (or 
chronologically) separate, disparate lesions of very different grades, we caution careful 
correlation between imaging, sampling, and histopathology for surveillance or sampling 
protocols.  
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FIGURE LEGENDS 
 
Figure 1. Clinical findings at presentation for Case 1 included an enhancing, multinodular, 
focally calcified left kidney masses arising in the upper, interpolar, and lower poles of the kidney 
(A). An enlarged ipsilateral adrenal gland excised at nephrectomy was confirmed to be an 
adrenocortical adenoma (B). Multiple nodular cutaneous tumors seen on preoperative imaging 
and interpreted as suspicious for metastasis (C, arrows), proved to be cutaneous, pilar-type 
leiomyomata (D). Fumarate hydratase (FH) immunostain was negative in this tumor (inset, see 
internal control positive endothelium), a pattern that has been interpreted as highly suspicious 
for Hereditary Leiomyomatosis-Renal Cell Carcinoma (HLRCC)-associated cutaneous 
leiomyomatosis39. 
 
Figure 2. The kidney tumor resected in Case 1 demonstrated grossly a partly exophytic 
multinodular mass with striking yellow gross morphology (A). At low power, a solid appearance 
was imparted by a tumor compos d of densely packed nests of cells with eosinophilic 
cytoplasm (B). At intermediate power, scattered foci with a more tubular and more microcystic 
appearance with dense pink luminal contents were noted (C). Similarly, one of the many tumor 
nodules had prominent stromal myxoedematous change (D), with occasional hobnail-shaped 
cells protruding into the center of tubules (inset). However, the predominantly solid and nested 
tumor was composed of cells with oncocytic morphology, variably flocculent cytoplasm, and 
nuclei with finely granular chromatin with scattered small nucleoli (E); stromal mast cells were 
very prevalent (arrows). Expression of FH was lost by immunohistochemistry (F, note internal 
control expression in endothelial cells), while expression of 2SC was strongly induced and 
SDHA and SDHB expression retained (insets, each as indicated).  
 
Figure 3. Case 2, arising in an 11-year-old male with proven HLRCC showed a dilated cyst, 
with adjacent cellular proliferation (A). At intermediate power (B), the carcinoma is seen to be 
composed of tubules and nests of oncocytic cells with indistinct nucleoli.  At higher power, (C) 
flocculent eosinophilic cytoplasm is readily apparent, as are several examples of large 
cytoplasmic vacuoles, containing eosinophilic inclusions (arrows). By immunohistochemistry 
(D), the tumor lacked expression of FH (note weak retention in internal control 
microvasculature) and showed induction of strong nucleocytoplasmic 2SC, and retained SDHB, 
and SDHA (insets, as indicated).  
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Figure 4. In the third case, the nephrectomy showed a kidney with striking polycystic 
background (A), wherein a 0.4cm solid nodule was apparent. At intermediate power, this tumor 
show a pattern of dense, nested and solid oncocytic carcinoma (B). Another tiny nodule with 
similar low power appearance was also identified between locules of cysts (C), showing a 
similar cytomorphology (D). The same kidney harbored an anatomically separate, synchronous 
tumor composed of high grade infiltrative, tubular and cribriform carcinoma (E) with large nuclei 
of high (ISUP) nucleolar grade, prominent nucleoli with perinuclear clearing and syncytial 
appearance (F). This starkly contrasted the ISUP nucleolar grade 2 features of the oncocytic 
tumors (G, at the same magnification as F for comparison). Both tumors demonstrated loss of 
FH expression, induction of 2SC expression, and retained SDHB by IHC (not shown), while 
targeted next-generation sequencing demonstrated identical homozygous FH p.K80fs 
mutations. Comparing genome wide copy number calls via scatter plot of log2 gene-level copy 
number ratios between the oncocytic tumor (ordinate) and the synchronous high grade tumor 
(abscissa), the oncocytic tumor lacked gains at 8q (red) and losses of chromosome 18 (blue). 
 
Figure 5. In the fourth case, a partial nephrectomy was performed sampling a solid lesion in an 
enlarged multicystic kidney. A 5cm solid nodule was seen (A, arrows) adjacent to a multicystic 
lesion, composed of nests of oncocytic cells with even chromatin and indistinct nucleoli (B). The 
cytoplasm was variably flocculent, with infrequent vacuoles with eosinophilic inclusion-like 
bodies (arrow).  FH expression was lost, while strong/diffuse nucleocytoplasmic 2SC was 
identified (insets); SDHA and SDHB expression were retained (not shown). Though completion 
nephrectomy was recommended, it was performed 4 years later, showing a high grade, 
infiltrative RCC with glandular, solid, and tubulocystic growth patterns, invasive of renal sinus 
adipose (C). The cytology of this later tumor, which was also FH-deficient (D, inset) was 
markedly different, with large, variably shaped nuclei with prominent, inclusion-like nucleoli with 
perinuclear halos (D), much more in the spectrum described for typical FH-deficient RCCs.  
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